Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 30;12(8):713.
doi: 10.3390/pharmaceutics12080713.

Prevalence of Potential Drug-Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital

Gracia Santos-Díaz  1 , Ana María Pérez-Pico  2 , Miguel Ángel Suárez-Santisteban  1   3 , Vanesa García-Bernalt  3 , Raquel Mayordomo  4 , Pedro Dorado  1
Affiliations

Prevalence of Potential Drug-Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital

Gracia Santos-Díaz et al. Pharmaceutics. .

Abstract

Chronic kidney disease (CKD) is a major health problem worldwide and, in Spain, it is present in 15.1% of individuals. CKD is frequently associated with some comorbidities and patients need to be prescribed multiple medications. Polypharmacy increases the risk of adverse drug reactions (ADRs). There are no published studies evaluating the prevalence of potential drug-drug interactions (pDDIs) among CKD patients in any European country. This study was aimed to determine the prevalence, pattern, and factors associated with pDDIs among CKD patients using a drug interactions program. An observational cross-sectional study was carried out at Plasencia Hospital, located in Spain. Data were collected among patients with CKD diagnoses and pDDIs were assessed by the Lexicomp® Drug Interactions platform. Data were obtained from 112 CKD patients. A total number of 957 prescribed medications were acknowledged, and 928 pDDIs were identified in 91% of patients. Age and concomitant drugs were significantly associated with the number of pDDIs (p < 0.05). According to the results, the use of programs for the determination of pDDIs (such as Lexicomp®) is recommended in the clinical practice of CKD patients in order to avoid serious adverse effects, as is paying attention to contraindicated drug combinations.

Keywords: Lexicomp; adverse drug reactions; chronic kidney disease; drug–drug interactions; polypharmacy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Frequency of main drugs with potential drug–drug interactions (n = 928).
See this image and copyright information in PMC

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013;3:1–150.
    1. GBD Chronic Kidney Disease Collaboration Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–733. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed
    1. Gorostidi M., Sánchez-Martínez M., Ruilope L.M., Graciani A., de la Cruz J.J., Santamaría R., del Pino M., Guallar-Castillón P., de Álvaro F., Rodríguez-Artalejo F., et al. Prevalencia de enfermedad renal crónica en España: Impacto de la acumulación de factores de riesgo cardiovascular. Nefrologia. 2018;38:606–615. doi: 10.1016/j.nefro.2018.04.004. - DOI - PubMed
    1. Webster A., Nagler E., Morton R., Masson P. Chronic Kidney Disease. Lancet. 2017;389:1238–1252. doi: 10.1016/S0140-6736(16)32064-5. - DOI - PubMed
    1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010;87:4–14. doi: 10.1016/j.diabres.2009.10.007. - DOI - PubMed

LinkOut - more resources